





Physiologic response to hypobaric hypoxia




Oxygen transport at extreme altitude

 $CaO2 = SaO2 \times Hb \times 1.39 + (PaO2 \times 0.03)$



Headache mountains and fever slopes




Chinese Headache Mountain c. 30 BC

(Tseen Han Shoo Book 96)

"...Again passing the Great
Headache Mountains, the Little
Headache mountain, the Red
Lands and the Fever Slope, men's
bodies became feverish, they lose
color and are attacked with
headache and vomiting".

High altitude illnesses (Puna)




High altitude illnesses


Acute mountain sickness/HACE

Axiatl T₂-weighted MRI in HACE **Edema of the splenium** Hackett et al JAMA 1998; 280: 1920-25

High altitude pulmonary edema



Symptoms of acute mountain sickness



Signs of acute mountain sickness



- Peripheral edema
 - → Orbital, hands, feeds
- Lip cyanoses
- Mental dysfunction
- Ataxia

The Lake Louise consensus on definition of altitude illness


Acute mountain sickness (AMS)

- > Headache +
 - Gastrointestinal symptoms (anorexia, nausea, vomiting)
 - > Fatigue or weakness
 - Dizziness or lightheadedness
 - > Difficulty sleeping
- "Endstage" of AMS = High altitude cerebral edema (HACE)
 - > Changes in mental status and/or
 - > Ataxia in the presence of AMS


The brain in acute hypoxia

- O cerebral blood flow
- U impaired autoregulation
- vessel permeability
 vasogenic edema
 edema corpus callosum
 and splenium


• Intracellular edema
(cytotoxic edema)
Mitocondrial
dysfunction
Lactat-acidosis
O³-, NOx



Incidence of acute mountain sickness in the Swiss Alps




Prevention of high altitude illness



Rate of ascent < 600 m / day


Numbers od nights > 2500m

Individual susceptibility is the major risk factor for AMS at 4559m



Schneider et al Med Sci Sports Exerc 2002,; 34:1886

Risk factors and prevalence of AMS during ascent to 4559m



Medical prophylaxis and treatment of AMS

Azetazoalmide


- Mechanism
 - Metabolic acidosis
- > Effect
 - Ventilation
 - O Periodic breathing
 - \Rightarrow **1** PaO₂
- Dosage
 - 125 250 mg bid
- Indikation
 - AMS prophylaxis
 - Therapy of mild AMS

Dexamethasone

- Mechanism
 - O Cytoxines synthesis
 - O Cellular Na+-Transport
- > Effect
 - O capillary leak
 - • diureses (Kidney tubuli)
 - Water reabsorption (Alv. space)
 - ⇒ U Central dysfunction
 - \Rightarrow **1** PaO₂
- Dosage
 - 8 16 mg per day
 - Therapy of moderate to severe AMS

High Altitude Pulmonary Edema

Central distributed infiltrates



Peripheral distributed infiltrates



Clinical Presentation of HAPE

Symptoms and Signs

- Weakness / Decreased Exercise Performance
- Dyspnoe at Rest, Othopnoe
- Cough, Cracels bloody sputum
- Chest tightness or congestion
- Tachycarda > 90/min
- Tachypnoe > 25/min
- Cyanosis, SpO2 < 70% (4500m)
- Lung: Rales or wheezing
- Body Temperature > 37.4 ° C




Clinical diagnosis of high altitude pulmonary edema

		Rx's without HAPE 122	Rx's with HAPE 32
Dyspnea at rest	(11)	9%	91%
Tachypnea (> 25 breath/min)	(20)	55%	45%
Lung auscultation	ո։		
no rales	(127)	85%	15%
rales +	(18)	61%	30%
rales ++	(9)	33%	67%

(Data were obtained from 60 subjects studied during 3 consecutive days at the altitude of 4559 m)

High altitude pulmonary edema may develop with only mild AMS



^{*} p < 0.05 vs. mild and severe AMS; ** p < 0.01 vs. no-AMS; # p < 0.01 vs mild AMS

The Lake Louise consensus on definition of altitude illness

High altitude pulmonary edema (HAPE)

Symptoms: (at least two)

- Dyspnoe at rest
- Cough
- Weakness or decreased exercise performance
- Chest tightness or congestion

Signs: (at least two)


- Rales and wheezing in at least one lung field
- Central cyanosis
- Tachypnoe
- Tachycardia

Pathophysiology of High Altitude Pulmonary edema: The overperfusion of PC and Venoconstriction


HAPE: patchy distributed infiltrates







Elevated pulmonary capillary pressure leads to a leakage of blood gas barrier




Factors known to be associated with an increased risk of HAPE

Individual susceptibility


Additional risk factors

- Open foramen ovale
- Congenital atresia/hypoplasia of a pulmonary artery
- Pulmonary hypertension at low altitude
- Pulmonary embolism
- Systemic inflammation decreasing pulmonary capillaries edema formation threshold



Rationale for Prevention and Treatment Based on Pathophysiology

High Altitude Pulmonary edema



Inhibition of excessive hypoxic pulmonary vasoconstriction

- Vasodilators
 - Calcium channel blokers
 - Phosphodiestherase 5 inhibitors
- Improve nitric oxide availability
 - Phosphodiestherase 5 inhibitors
 - Glucocorticoids
- Improve water reabsorption
 - Beta-2-agonists
 - Glucocorticoids

Prophylaxis of High Altitude Pulmonary Edema (HAPE)

HAPE

Trekking/climbing above 2500m

Slow ascent

300 m/day

Nifedipine

CR30-60 every 24 h or 20 mg every 24 h Start

Tadalafil

Start 24h before ascent 24h before ascent

+ AMS > 2 AMS Symptoms

Azetazolamide

125 mg every 12 h

HAPE & AMS

Busienesstrip above 2500m

Rapid ascent with a short sojourn

1000 m/day + < 5 days above 2500m

Dexamethasone

4-8mg every 12 h Start 24 h before ascent

Treatment of High Altitude Pulmonary Edema (HAPE)

Mild-AMS
≤ 2 AMS Symptoms

Azetazolamide 125 mg every 12 h **HAPE**

4-6 I/min O₂
+
Nifedipin 20 mg
or
Sildenafil 50mg
every 8 h

Descent > 1000m

Mild/Severe AMS


> 2 AMS Symptoms

Dexamethasone


8 mg loading dose 4 mg every 6 h



Hypothermia mechanisms



Water temperature and survival



Hypothermia Classification

Acute

 Ice water, glacier crevasse


Subacute

Avalange, snow and wind

Chronic

Exhaustion

Hypo- thermia stage	Core temperature	Signs
	35° - 32°	Patient alert, shivering
II	32° - 28°	Patient drowsy, nonshivering
Ш	28° - 24°	Patient unconscious
IV	< 24°	Patient not breathing



Risk factors for cold injuries

Behavioural

- Inadequate clothing and shelter
- Alcohol and other drug use
- Psychiatric illness
- Smoking


Mechanical

- Tightly constrictive clothing (too many socks)
- Contact with heat conductive materials
- Rings on fingers
- Immobility (bivouac, avalanche)

Physiological

- Genetic susceptibility
- Dehydration and hypovolaemia
- Hypoxia and hypothermia
- Diabetes, atherosclerosis, vasculitis
- Raynaud's phenomenon
- Vasoconstrictive drugs
- Sweating or hyperhydrosis (heat loss)
- Previous frostbite


Hypothermia in avalanche victims



Management of the hypothermic patient

Stage I, II and III

Assessment of the patient No Hypothermia I–II: Administer hot, sweet drinks · Change clothing if practicable · Transport to nearest hospital with intensive-care unit Breathing?? No Hypothermia III: Intubate, ventilate with warm humidified oxygen Transport to hospital with hypothermia experience or unit with cardiopulmonary bypass



Hypothermia summary

- Prevention is vital non-freezing cold injury (Hypothermia) and for both frostbite.
- Early recognition and treatment will limit the extent of the injury.
- Hypothermia: warm slowly, Stage IV (Extra corporal circulation)
- Frostbite: warm quickly, defer surgery.
- Transfer to a referral center




Elevated ambient temperature



Definition of hypertherima

Hyperthermia is a non-regulated elevation of core body temperature (heat stress, heat stroke) caused by the inability of the effector mechanisms to eliminate heat from the body adequately.

Response to heat exposure



Bouchama & Knochel, NEJM 2002, 346:1978

Heart related illness

Туре	Causes	Clinical Presentation	Treatment
Heat edema	Vasodilation	Dependent edema BT normal	Elevate extremities
Heart rash	Sweating saturated skin surface and clogs sweat ducts	Pruritic rash BT normal	Cooling Mild antihistaminic
Heat cramps	Poor acclimatization, negative sodium balance	Twitches, fasciculations, painful spasms, sustained muscle contraction, BT normal	Appropriate water and sodium intake
Heat syncope	Dehydration, vasodilation, decreased cardiac output	Orthostatic hypotension, loss of consciousness, core BT normal	rehydration
Heat exhaustion	Compromised circulation and cooling mechanisms	Fatigue, malaise, headache, nausea, vomiting, muscle cramping, profuse sweating, hypotension, tachycardia	Stop exercise, remove clots, fluids, monitor vital signs

Relationship between ambient temperature and heat illness

Celsius	Comments	
27–32 °C	Caution — fatigue is possible with prolonged exposure and activity. Continuing activity could result in heat cramps	
32–41 °C	Extreme caution — heat cramps, and heat exhaustion are possible. Continuing activity could result in heat stroke	
41–45 °C	Danger — heat cramps, and heat exhaustion are likely; heat stroke is probable with continued activity	
Over 45 °C	Extreme danger — heat stroke is imminent	

Heat stroke

Definition

- ➤ Severe illness characterized by a core temperature > 40° C and central nervous system abnormalities such as delirium, convulsions or coma resulting from exposure to environmental heat or strenuous physical exercise
 - It is a form of hyperthermia associated with systemic inflammatory response leading to a syndrome of multiorgan dysfunction in which encephalopathy predominates

Heat stroke

Clinical and metabolic manifestations


- hyperthermia (40° C 47° C) *
- central nervous system dysfunction (inappropriate behavior or delirium or coma) *
- > Tachycardia & Hyperventilation (all patients)
- Hypotension (25% of the patients)
- Metabolic acidosis (exertional heat stroke)
- Rabdomyolasis (exertional heat stroke)

Heat stroke

Pathogenesis

- Thermoregulatory failure: inability to maintain body temperature at 37° C because of insufficient adaptation to heat (several weeks)
 - Inability to increase cardiac output to peripheral circulation
- Exaggerated acute-phase response (systemic inflammatory response) following ischemia of the gut and intestinal hyperpermeability (endotoxies)
- Low level of expression of heat-shock proteins
 - Aging, lack of acclimatization, genetic polymorphisms

Heat stroke: Pathogenesis



Bouchama & Knochel, NEJM 2002, 346:1978

Heat stroke: Pathophysiology

- Local inflammation
 - > Muscle
- Systemic progression
 - Monocyte, neutrophils, endothelial cells
 - Endotoxinemia following gut ischemia
 - DIC, microvascular thrombosis
- Multi-organ failure

to Heat Stroke to Heat Stroke Muscle L-selectin Decrease in protein C. ICAM-1 Interleukin-1, protein S, interleukin-6 β₂ integrin antithrombin III Tissue factor Monocyte Thrombin Fibrin monomers Monocyte Neutrophil Increase in TNF-α, Inhibition of interleukin-1 fibrinolysis interleukin-6. interleukin-10 Increase in Clot von Willebrand Increase in Endotoxin factor antigen E-selectin Increase in thrombomodulin Intestine

Coagulation Response

Inflammatory Response

Bouchama & Knochel, NEJM 2002, 346:1978

Heat Stroke

Treatment

- Cooling (keep core temperature < 39.4° C)</p>
 - External: ice slush, cooling blankets or vest, cooling catheter, (hemofiltration)
 - Avoid shivering: sedation
- > Fluid resuscitation and vasopressors like in sepsis
 - Prevent myoglobin induced renal failure
- Pharmacologic agents are ineffective
 - Dandrolene (randomized controlled trial)
 - Antipyretic agents

